Shares of BioCryst's gap up as influenza drug shows promise in study Print E-mail
By Staff and Wire Reports   
Friday, 17 July 2009 09:27

July 17 (Reuters) - BioCryst Pharmaceuticals (NASDAQ:BCRX) said a late-stage study testing the intravenous form of its experimental influenza drug peramivir showed the drug was not inferior to another flu drug, Tamiflu, sending its shares up 50 percent. The study, sponsored by BioCryst's partner Shionogi & Co Ltd of Japan, compared the efficacy and safety of a single dose of peramivir -- either 300 mg or 600 mg -- with oral 75 mg of Tamiflu.

Both the 300 mg and 600 mg single dose peramivir groups demonstrated non-inferiority to Tamiflu.

A total of 1,099 patients were enrolled at 146 centers, the company said.

BioCryst said it is currently finalizing its plans for late-stage studies of peramivir intended to support U.S. regulatory approval, and also continuing to support the pre-emergency use authorization review of peramivir by the regulators.

In May, BioCryst said government agencies were considering the future option of providing intravenous peramivir through an emergency use authorization in the event of a severe influenza outbreak with significant hospitalizations. [ID:nBNG251032]

Shares of the company were up 50 percent at $6.30 in premarket trade. They closed at $4.22 Thursday on Nasdaq. (Reporting by Shailesh Kuber and Esha Dey in Bangalore; Editing by Aradhana Aravindan)




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter